Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Fluoropyrimidine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 128Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer

    02 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260130221586/en/Exelixis-Announces-U.S.-FDA-Accepted-the-New-Drug-Application-for-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-for-Patients-with-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    02 Feb 2026
    Share Share
    EC Approves KEYTRUDAPlus Trastuzumab and Chemotherapy as First-Line Treatment
    EC Approves KEYTRUDAPlus Trastuzumab and Chemotherapy as First-Line Treatment

    29 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230829956930/en

    BUSINESSWIRE
    29 Aug 2023
    Share Share
    FDA approves Taiho's Lonsurf with bevacizumab for metastatic colorectal cancer
    FDA approves Taiho's Lonsurf with bevacizumab for metastatic colorectal cancer

    03 Aug 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/fda-approves-taihos-lonsurf-with-bevacizumab-for-third-line-metastatic-colorectal-cancer/

    Zachary Brennan ENDPTS
    03 Aug 2023
    Share Share
    Merck’s KEYTRUDA Plus Chemotherapy Improved Overall Survival in GEJ
    Merck’s KEYTRUDA Plus Chemotherapy Improved Overall Survival in GEJ

    17 Feb 2023

    // PRESS RELEASE

    https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-alone-in-patients-with-her2-negative-gastric-or-gastroesophageal-junction/

    PRESS RELEASE
    17 Feb 2023
    Share Share
    Seagen Announces FDA Accelerated Approval of TUKYSA with Trastuzumab
    Seagen Announces FDA Accelerated Approval of TUKYSA with Trastuzumab

    19 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221222005382/en/Seagen-Announces-FDA-Accelerated-Approval-of-TUKYSA%C2%AE-tucatinib-in-Combination-with-Trastuzumab-for-People-with-Previously-Treated-RAS-Wild-Type-HER2-Positive-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    19 Jan 2023
    Share Share
    Agilent Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include ESCC
    Agilent Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include ESCC

    05 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220405005750/en

    BUSINESSWIRE
    05 Apr 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.